Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

GLPG-0492

From Wikipedia, the free encyclopedia
Medication
Pharmaceutical compound
GLPG-0492
Legal status
Legal status
Identifiers
  • 4-[(4R)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
CAS Number
PubChemCID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H14F3N3O3
Molar mass389.334 g·mol−1
3D model (JSmol)
  • CN1C(=O)N(C(=O)[C@]1(CO)C2=CC=CC=C2)C3=CC(=C(C=C3)C#N)C(F)(F)F
  • InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3/t18-/m0/s1
  • Key:VAJGULUVTFDTAS-SFHVURJKSA-N

GLPG-0492 (DT-200) is a drug which acts as aselective androgen receptor modulator (SARM). It has been investigated for the treatment ofcachexia andmuscular dystrophy.[1][2][3][4][5][6]

See also

[edit]

References

[edit]
  1. ^Nique F, Hebbe S, Triballeau N, Peixoto C, Lefrançois JM, Jary H, et al. (October 2012). "Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator".Journal of Medicinal Chemistry.55 (19):8236–8247.doi:10.1021/jm300281x.PMID 22957947.
  2. ^Cozzoli A, Capogrosso RF, Sblendorio VT, Dinardo MM, Jagerschmidt C, Namour F, et al. (June 2013). "GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy".Pharmacological Research.72:9–24.doi:10.1016/j.phrs.2013.03.003.hdl:11586/62855.PMID 23523664.
  3. ^Blanqué R, Lepescheux L, Auberval M, Minet D, Merciris D, Cottereaux C, et al. (September 2014)."Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization".BMC Musculoskeletal Disorders.15 291.doi:10.1186/1471-2474-15-291.PMC 4167280.PMID 25185887.
  4. ^Zierau O, Kolodziejczyk A, Vollmer G, Machalz D, Wolber G, Thieme D, Keiler AM (May 2019). "Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay".The Journal of Steroid Biochemistry and Molecular Biology.189:81–86.doi:10.1016/j.jsbmb.2019.02.014.PMID 30825507.S2CID 72334106.
  5. ^Fonseca GW, Dworatzek E, Ebner N, Von Haehling S (August 2020). "Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials".Expert Opinion on Investigational Drugs.29 (8):881–891.doi:10.1080/13543784.2020.1777275.PMID 32476495.S2CID 219174372.
  6. ^Stacchini C, Botrè F, Comunità F, de la Torre X, Dima AP, Ricci M, Mazzarino M (February 2021). "Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography-mass spectrometry-based techniques".Journal of Pharmaceutical and Biomedical Analysis.195 113849.doi:10.1016/j.jpba.2020.113849.PMID 33383501.S2CID 229941017.
ARTooltip Androgen receptor
Agonists
SARMsTooltip Selective androgen receptor modulator
Antagonists
GPRC6A
Agonists
Stub icon

Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=GLPG-0492&oldid=1318940736"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp